Immune checkpoint inhibitors (ICIs) including anti‐programmed cell death protein 1 (PD‐1) and anti‐programmed death‐ligand 1 (PD‐L1) antibodies have dramatically improved treatment outcomes in advanced stage non‐small cell lung cancer (NSCLC).1, 2, 3, 4, 5. This evidence concerns the gene PDCD1 and lung cancer.